Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 491-504

  Milczarek, Magdalena ^a   Filip Psurska, Beata ^a   ́Sw̧Ietnicki, Wiesław ^b   Kutner, Andrzej ^c   Wietrzyk, Joanna ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW RESEARCH CENTRE EIT   (Poland)

^c INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

5 fluorouracil; Colon cancer; Combined treatment; Vitamin d analogs

Indexed keywords

CALCIPOTRIOL; CALCITRIOL; CASPASE 3; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PRI 2191; PRI 2205; PROTEIN P53; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; 1 ALPHA,24-DIHYDROXYVITAMIN D3; ANTINEOPLASTIC ANTIMETABOLITE; CALCITRIOL RECEPTOR; DIHYDROXYCOLECALCIFEROL; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL POPULATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HT 29 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CALCITRIOL; CELL CYCLE; COLONIC NEOPLASMS; DIHYDROXYCHOLECALCIFEROLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; MICE; MICE, INBRED NOD; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; VITAMIN D; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903203474     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3247     Document Type: Article

References (73)

1. Lamprecht SA and Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3: 601-614, 2003. (Pubitemid 37328832)
2. McCarthy TC, Li X and Sinal CJ: Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280: 23232-23242, 2005. (Pubitemid 40853235)
3. Pritchard RS, Baron JA and Gerhardsson de Verdier M: Dietary calcium, vitamin D, and the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol Biomarkers Prev 5: 897-900, 1996. (Pubitemid 26382983)
4. Terry P, Baron JA, Bergkvist L, Holmberg L and Wolk A: Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer 43: 39-46, 2002. (Pubitemid 35387254)
5. 3 analogs, in-vitro and in-vivo studies. Invest New Drugs 31: 247-255, 2013.
6. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR and Heber D: Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 95: 1765-1771, 2003. (Pubitemid 38008899)
7. Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Marshall J, Shike M, Weissfeld J, Brewer B, Schatzkin A and Lanza E: The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 135: 252-259, 2005. (Pubitemid 40194487)
8. Baniahmad A and Tsai MJ: Mechanisms of transcriptional activation by steroid hormone receptors. J Cell Biochem 51: 151-156, 1993. (Pubitemid 23058571)
9. Nagpal S, Na S and Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687, 2005. (Pubitemid 41127276)
10. Saramaki A, Banwell CM, Campbell MJ and Carlberg C: Regulation of the human p21 (waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 34: 543-554, 2006. (Pubitemid 43240242)
11. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, Lombardia L, Herrera M, Dominguez O, Segura MF, Bonilla F, Hernando E and Munoz A: MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 21: 2157-2165, 2012.
12. Matusiak D, Murillo G, Carroll RE, Mehta RG and Benya RV: Expression of vitamin D receptor and 25-hydroxy-vitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol Biomarkers Prev 14: 2370-2376, 2005. (Pubitemid 41437839)
13. Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM and Holick MF: Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 135: 2350-2354, 2005. (Pubitemid 41429589)
14. Mokady E, Schwartz B, Shany S and Lamprecht SA: A protective role of dietary vitamin D3 i n r at c olon c arcinogenesis. Nutr Cancer 38: 65-73, 2000. (Pubitemid 32377945)
15. Hummel DM, Thiem U, Hobaus J, Mesteri I, Gober L, Stremnitzer C, Graca J, Obermayer-Pietsch B and Kallay E: Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. J Steroid Biochem Mol Biol 136: 284-288, 2013.
16. Larriba MJ, Ordonez-Moran P, Chicote I, Martin-Fernandez G, Puig I, Munoz A and Palmer HG: Vitamin D receptor deficiency enhances Wnt/β-catenin signaling and tumor burden in colon cancer. PLoS ONE 6: e23524, 2011.
17. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK and Malone JM: Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853, 1991.
18. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA and Koren R: 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999. (Pubitemid 29086740)
19. Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W and Radzikowski C: Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 21: 1925-1929, 2001. (Pubitemid 32728932)
20. Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A and Opolski A: Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 26: 2701-2705, 2006. (Pubitemid 44155551)
21. Opolski A, Wietrzyk J, Siwinska A, Marcinkowska E, Chrobak A, Radzikowski C and Kutner A: Biological activity in vitro of side-chain modified analogues of calcitriol. Curr Pharm Des 6: 755-765, 2000. (Pubitemid 30396414)
22. 3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Basic Clin Pharmacol Toxicol 109: 97-102, 2011.
23. 3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
24. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E and Ikeda K: Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53: 2534-2537, 1993. (Pubitemid 23168018)
25. Chodyński M, Wietrzyk J, Marcinkowska E, Opolski A, Szelejewski W and Kutner A: Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro- 24a-homo- 1,25-dihydroxyergocalciferol and congeners. Steroids 67: 789-798, 2002. (Pubitemid 34765668)
26. Wietrzyk J, Chodynski M, Fitak H, Wojdat E, Kutner A and Opolski A: Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs 18: 447-457, 2007. (Pubitemid 46712408)
27. Wietrzyk J, Nevozhay D, Filip B, Milczarek M and Kutner A: The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res 27: 3387-3398, 2007. (Pubitemid 47607566)
28. Wietrzyk J, Pelczynska M, Madej J, Dzimira S, Kusnierczyk H, Kutner A, Szelejewski W and Opolski A: Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 69: 629-635, 2004. (Pubitemid 39297701)
29. Wietrzyk J, Nevozhay D, Milczarek M, Filip B and Kutner A: Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol 62: 787-797, 2008.
30. Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A and Wietrzyk J: Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 33: 433-444, 2013.
31. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994. (Pubitemid 24359290)
32. Sun XX, Dai MS and Lu H: 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 282: 8052-8059, 2007.
33. Chakrabarty S, Radjendirane V, Appelman H and Varani J: Extracellular calcium and calcium sensing receptor function in human colon carcinomas: promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res 63: 67-71, 2003. (Pubitemid 36070421)
34. 2+ in colon carcinoma is dependent on calcium-sensing receptor expression and function. Int J Cancer 121: 1455-1462, 2007.
35. 3. Cancer Res 65: 493-498, 2005.
36. Wang X, Chen W, Singh N, Promkan M and Liu G: Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells. Int J Oncol 36: 1573-1580, 2010.
37. Liu G, Hu X and Chakrabarty S: Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 126: 631-639, 2010.
38. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM and Ackland SP: Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253, 2000.
39. Kim R, Emi M, Tanabe K, Uchida Y and Arihiro K: The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 32: 269-277, 2006.
40. Sastry GM, Adzhigirey M, Day T, Annabhimoju R and Sherman W: Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27: 221-234, 2013.
41. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC and Mainz DT: Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196, 2006. (Pubitemid 44595196)
42. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT and Banks JL: Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759, 2004. (Pubitemid 38380918)
43. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P and Shenkin PS: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749, 2004. (Pubitemid 38380917)
44. Li J, Abel R, Zhu K, Cao Y, Zhao S and Friesner RA: The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins 79: 2794-2812, 2011.
45. Hou T, Wang J, Li Y and Wang W: Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51: 69-82, 2011.
46. Hou T, Wang J, Li Y and Wang W: Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32: 866-877, 2011.
47. Rastelli G, Del Rio A, Degliesposti G and Sgobba M: Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 31: 797-810, 2010.
48. Danilenko M and Studzinski GP: Enhancement by other compounds of the anti-cancer activity of vitamin D3 and its analogs. Exp Cell Res 298: 339-358, 2004. (Pubitemid 38950853)
49. Milczarek M, Psurski M, Kutner A and Wietrzyk J: Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13: 294, 2013.
50. Zhao X and Feldman D: Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 132: 1808-1814, 1993. (Pubitemid 23110559)
51. Gaschott T, Werz O, Steinmeyer A, Steinhilber D and Stein J: Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 288: 690-696, 2001. (Pubitemid 33030085)
52. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M and Munoz A: Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154: 369-387, 2001. (Pubitemid 34286147)
53. Wietrzyk J, Opolski A, Madej J and Radzikowski C: Antitumour and antimetastatic effect of genistein alone or combined with cyclophosphamide in mice transplanted with various tumours depends on the route of tumour transplantation. In Vivo 14: 357-362, 2000. (Pubitemid 30315861)
54. Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL and Onate SA: Altered VDR-mediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol 103: 731-736, 2007. (Pubitemid 46401318)
55. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res 26: 2515-2524, 2006. (Pubitemid 44155530)
56. Tocchini-Valentini G, Rochel N, Wurtz JM and Moras D: Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and secocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification. J Med Chem 47: 1956-1961, 2004. (Pubitemid 38453914)
57. Matsunaga T, Yamamoto M, Mimura H, Ohta T, Kiyoki M, Ohba T, Naruchi T, Hosoi J and Kuroki T: 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol 17: 135-142, 1990. (Pubitemid 20195651)
58. Bouillon R, Allewaert K, Xiang DZ, Tan BK and van Baelen HJ: Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 6: 1051-1057, 1991.
59. Xu RX, Lambert MH, Wisely BB, et al: A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer Mol Cell 16: 919-928, 2004. (Pubitemid 40018402)
60. Wu B, Li S and Dong D: 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR. Drug Discov Today 18: 574-581, 2013.
61. Sutton AL and MacDonald PN: Vitamin D: more than a 'bone-a-fide' hormone Mol Endocrinol 17: 777-791, 2003. (Pubitemid 36539572)
62. Moreau A, Maurel P, Vilarem MJ and Pascussi JM: Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem Biophys Res Commun 360: 76-82, 2007. (Pubitemid 46990325)
63. Cheng HT, Chen JY, Huang YC, Chang HC and Hung WC: Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem 98: 1450-1456, 2006.
64. Huang YC, Chen JY and Hung WC: Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Oncogene 23: 4856-4861, 2004.
65. Diaz GD, Paraskeva C, Thomas MG, Binderup L and Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60: 2304-2312, 2000. (Pubitemid 30225198)
66. Koren R, Wacksberg S, Weitsman GE and Ravid A: Calcitriol sensitizes colon cancer cells to H2O2-induced cytotoxicity while inhibiting caspase activation. J Steroid Biochem Mol Biol 101: 151-160, 2006. (Pubitemid 44311482)
67. Meng J, Zhang HH, Zhou CX, Li C, Zhang F and Mei QB: The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep 28: 384-388, 2012.
68. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M and Rotter V: Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17: 273-285, 2010.
69. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
70. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181, 2001. (Pubitemid 32751613)
71. Mader RM, Muler M and Steger G: Resistance to 5-fluorouracil. Gen Pharmacol 31: 661-666, 1998. (Pubitemid 28520040)
72. Takagi K, Sowa Y, Cevik OM, Nakanishi R and Sakai T: CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells. Int J Oncol 32: 1105-1110, 2008.
73. Watanabe M, Sowa Y, Yogosawa M and Sakai T: Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci 104: 687-693, 2013.